San Diego-based Regulus Therapeutics, the developer of mircoRNA therapies, said today it has named Neil Gibson as its new chief scientific officer. Gibson was most recently the chief scientific officer and oncology therapeutics head at Pfizer’s oncology research unit in La Jolla, CA. Gibson replaces Peter Linsley, who left last month to join Bothell, WA-based AVI Biopharma (NASDAQ: [[ticker:AVII]]).
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
